Alexander Heinzel1,2, Dima Boghos3, Felix M Mottaghy4, Florian Gaertner5, Markus Essler5, Dirk von Mallek3, Hojjat Ahmadzadehfar5. 1. Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. aheinzel@ukaachen.de. 2. Institute for Neuroscience and Medicine (INM-4), Research Centre Jülich, Jülich, Germany. aheinzel@ukaachen.de. 3. Department of Nuclear Medicine, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany. 4. Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands. 5. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Abstract
PURPOSE: To evaluate the use of 68Ga-PSMA PET/CT for monitoring response to 177Lu-617 PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS: Patients from the University Hospital Bonn and the University Hospital Aachen were retrospectively reviewed for this study. We included 48 patients with mCRPC who were treated with 177Lu-PSMA-617 and whose records included 68Ga-PSMA PET/CT imaging before the first and after the third or fourth treatment cycle. A treatment response based on 68Ga-PSMA PET/CT was defined according to a modified version of the PERCIST criteria. A decline in PSA level of ≥50% was considered the reference standard. The sensitivity, specificity, positive and negative predictive values, and ROC curves were calculated, and patient survival times in relation to the PET results were also analysed. RESULTS: 68Ga-PSMA PET/CT had a sensitivity of about 85% and a specificity of between 55% and 65%. The negative and positive predictive values ranged between 70% and 78%. The fitted ROC area was 0.70. The survival time was about 19.6 months in patients with a treatment response, while nonresponders had a survival time of about 15.9 months. However, this difference between the groups was not statistically significant. CONCLUSION: Our results indicate that 68Ga-PSMA PET/CT could be a useful tool for the evaluation of response to 177Lu-PSMA-617 radioligand therapy within a theranostic framework.
PURPOSE: To evaluate the use of 68Ga-PSMA PET/CT for monitoring response to 177Lu-617 PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS:Patients from the University Hospital Bonn and the University Hospital Aachen were retrospectively reviewed for this study. We included 48 patients with mCRPC who were treated with 177Lu-PSMA-617 and whose records included 68Ga-PSMA PET/CT imaging before the first and after the third or fourth treatment cycle. A treatment response based on 68Ga-PSMA PET/CT was defined according to a modified version of the PERCIST criteria. A decline in PSA level of ≥50% was considered the reference standard. The sensitivity, specificity, positive and negative predictive values, and ROC curves were calculated, and patient survival times in relation to the PET results were also analysed. RESULTS: 68Ga-PSMA PET/CT had a sensitivity of about 85% and a specificity of between 55% and 65%. The negative and positive predictive values ranged between 70% and 78%. The fitted ROC area was 0.70. The survival time was about 19.6 months in patients with a treatment response, while nonresponders had a survival time of about 15.9 months. However, this difference between the groups was not statistically significant. CONCLUSION: Our results indicate that 68Ga-PSMA PET/CT could be a useful tool for the evaluation of response to 177Lu-PSMA-617 radioligand therapy within a theranostic framework.
Authors: Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller Journal: Lancet Oncol Date: 2009-02-11 Impact factor: 41.316
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236
Authors: A M Hövels; R A M Heesakkers; E M Adang; G J Jager; S Strum; Y L Hoogeveen; J L Severens; J O Barentsz Journal: Clin Radiol Date: 2008-02-04 Impact factor: 2.350
Authors: Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2013-09-27 Impact factor: 9.236
Authors: Panagiotis J Vlachostergios; Muhammad Junaid Niaz; Myrto Skafida; Seyed Ali Mosallaie; Charlene Thomas; Paul J Christos; Joseph R Osborne; Ana M Molina; David M Nanus; Neil Harrison Bander; Scott T Tagawa Journal: Prostate Date: 2021-01-19 Impact factor: 4.104
Authors: Florian Rosar; Kalle Ribbat; Martin Ries; Johannes Linxweiler; Mark Bartholomä; Stephan Maus; Mathias Schreckenberger; Samer Ezziddin; Fadi Khreish Journal: EJNMMI Res Date: 2020-05-24 Impact factor: 3.138
Authors: Agnieszka Morgenroth; Ebru Tinkir; Andreas T J Vogg; Ramya Ambur Sankaranarayanan; Fatima Baazaoui; Felix M Mottaghy Journal: Breast Cancer Res Date: 2019-10-22 Impact factor: 6.466
Authors: Johanna Maffey-Steffan; Lorenza Scarpa; Anna Svirydenka; Bernhard Nilica; Christian Mair; Sabine Buxbaum; Jasmin Bektic; Elisabeth von Guggenberg; Christian Uprimny; Wolfgang Horninger; Irene Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-27 Impact factor: 9.236
Authors: Friederike Völter; Lena Mittlmeier; Astrid Gosewisch; Julia Brosch-Lenz; Franz Josef Gildehaus; Mathias Johannes Zacherl; Leonie Beyer; Christian G Stief; Adrien Holzgreve; Johannes Rübenthaler; Clemens C Cyran; Guido Böning; Peter Bartenstein; Andrei Todica; Harun Ilhan Journal: Diagnostics (Basel) Date: 2021-03-03
Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236